Investigators to Share Data from Three Late-Breaking Clinical Trials for the First Time at ATS 2024

A hotly anticipated Clinical Trials symposium at the ATS 2024 International Conference will feature recent breakthroughs in treating and managing pulmonary diseases. Breaking News: Clinical Trial Results in Pulmonary Medicine will take place on Monday, May 20, from 9:15 – 11:15 a.m. PT inside the San Diego Convention Center in Ballroom 20A (Upper Level).

Jennifer L. Taylor-Cousar, MD, MSc, ATSF
Jennifer Taylor-Cousar, MD, MSCS, ATSF

The leaders of three large phase two and phase three trials will present the results of their research for the first time in a public forum. The novel findings will provide imperative new insights related to therapeutic intervention for mycobacterium avium complex lung disease and two new drugs that could be utilized to treat moderate to severe COPD.

“The investigations featured in this session are the results from phase two and phase three trials that could change how we take care of patients in the relatively immediate future,” explained International Conference Committee Chair-Elect Jennifer Taylor-Cousar, MD, MSCS, ATSF.

Charles L. Daley, MD, professor of medicine and chief of the division of mycobacterial and respiratory infections at National Jewish Health, will review results from the ARISE study, a randomized, double-blind trial of amikacin liposome inhalation suspension in adults with newly diagnosed or recurrent mycobacterium avium complex lung disease (MACLD) to validate patient-reported outcome instruments and assess microbiological outcomes of treatment.

“The investigators in this trial looked at the use of liposomal amikacin to validate patient-reported outcomes, a measure understudied in patients with MACLD, and to determine if it impacts microbiologic outcomes,” Dr. Taylor-Cousar explained.

Dave Singh, MD, professor of respiratory pharmacology at the University of Manchester, will discuss the findings from the phase 2a COURSE study analyzing the efficacy and safety of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease.

“COPD is a disease characterized by chronic inflammation. This study is significant because while numerous treatments have made small changes in lung function or dyspnea related to COPD, there haven’t been many disease-modifying therapies,” Dr. Taylor-Cousar said.

Finally, Surya P. Bhatt, MD, MSPH, professor of pulmonary, allergy & critical care medicine and medical director of the Pulmonary Function and Exercise Physiology Lab at the University of Alabama at Birmingham, will present key findings from the phase 3 NOTUS trial exploring the efficacy and safety of dupilumab in patients with moderate to severe COPD and type 2 inflammation.

“There are some of the premier investigators in the world speaking at this session,” Dr. Taylor-Cousar said. “People get excited about this session because it provides first access to these groundbreaking results that they can take back to their clinics and, potentially, start utilizing for their patients with the knowledge they gleaned from this session at the International Conference.”

Don’t Miss ATS 2024 Highlights: On Demand

Don’t forget that ATS 2024 Highlights: On Demand are available to all conference registrants! On Demand will give you access to the Opening Ceremony, Plenary Session, Keynote Series, Clinical Year in Review, Adult Clinical Core Curriculum, and so much more. The topics will cover ILD, asthma, health equity, and CF, to name just a few. On Demand content will be accessible to all ATS 2024 full conference and On Demand registrants until March 2025.